ASIAN JOURNAL OF CLINICAL PERINATOLOGY AND PEDIATRIC BIOLOGY

VOLUME 1, 2026

Maternal Micronutrient Deficiency and Its Impact on Fetal Neurodevelopmental Biomarkers

*Parthiban Govindarajoo[1], Remya Vallathol[2], Priyanka C[3], Hardev Singh[3] and Kohinoor Pervin[4]

[1]Department of Anatomy, Faculty of Medicine, Manipal University College, Malaysia
[2]Department of Microbiology, Faculty of Medicine, Manipal University College, Malaysia
[3]School of Medicine, Perdana University, Damansara Heights, Kuala Lumpur, Malaysia
[4]Faculty of Medicine, AIMST University, Bedong, Kedah, Malaysia

*Correspondence: parthiban.govindarajoo@manipal.edu.my

Submitted: 12 Sep 2025, Revised: 02 Nov 2025, Accepted: 20 Jan 2026

https://doi.org/10.64799/ajcppb.V1.I1.6

Abstract

Micronutrients, which are important for brain development, influence fetal brain development, but how prenatal micronutrient deficiency affects early brain development is still not fully understood. The aim of this research is to determine the learnable absence of maternal micronutrient deficiency relations and fetal brain development biomarker(s) at birth, employing an integrated maternal-placental-fetal approach. The study illustrates coordinated changes in the fetal neurodevelopmental signaling deficiency related to the maternal micronutrient deficiency in neurotrophic, growth, and myelination biomarkers in the placental and cord blood of the myelination deficient maternal micronutrient. The multivariate analyses of the fetal biomarker profiles according to maternal micronutrient absence resulted in distinct and clear stratification which was indicative of the developmental lag of certain micronutrients employed the functional modeling of the non-linear relations. Of the fetal neurodevelopmental biomarkers, the absence of maternal micronutrients is indicative of the early structural vulnerabilities of the developing fetus. The research also highlighted the importance of nutritional interventions that are targeted during the prenatal period.

Keywords: maternal micronutrients; fetal neurodevelopment; cord blood biomarkers; placental transfer; prenatal risk stratification

1. Introduction

Preparation of the fetal brain relies on multiple factors, especially the precise coordination of genetic, metabolic, and environmental intrauterine signaling. Maternal micronutrients serve as critical regulators of this process. They go beyond the roles of normal dietary constituents, acting as biochemical cofactors for critical cellular events, such as proliferation, differentiation, synapse formation, and myelination. Additionally, during the entire gestation period, the fetal brain undergoes rapid and great structural and functional developments. This emphasizes the great sensitivity of the brain to any micronutrient disruption. Consequently, even the smallest deficiency of micronutrients during pregnancy can have adverse effects on the trajectories of neurodevelopmental outcomes of the fetus [1], [2].

Certain maternal micronutrients (e.g., iron, iodine, folate, vitamin B12, zinc, and choline) encourage and regulate neurodevelopment. Iron is critical for the production of some neurotransmitters, and also energy production within the mitochondria, and the functions of oligodendrocytes. Iodine is important for the production of thyroid hormones, which in turn drive neuronal migration and cortical layering [3], [4]. Both folate and vitamin B12 regulate one-carbon metabolism and DNA methylation, and are direct links between micronutrient levels and epigenetic control of neurodevelopmental genes [5], [6]. Zinc is involved in neurogenesis and synaptic plasticity, and choline is important for membrane biosynthesis and signaling via acetylcholine, among other things [7], [8]. Missing any of these micronutrients is detrimental for the programming of neurodevelopment during the sensitive periods of brain development.

Micronutrient insufficiency during pregnancy, is much more than a mere case of undernutrition. Rather, it is a state of undernutrition that embodies a unique biochemical stress within the maternal-placental-fetal system, causing changes in metabolic flux, redox equilibrium, signaling and alterations in the regulation of genes that integrate the maternal, placenta, and fetus. Deficiencies create blocks in certain enzymatic reactions, disrupt cofactor-dependent pathways, and create compensatory mechanisms that have negative consequences for the development of the fetal brain [9]. This 'biochemical' view is especially important in situations where maternal nutrition appears on the surface to be within normal ranges, but due to either poor bioavailability, poor absorption, or compromised placental transport, the fetus is functionally deficient from the maternal nutrition [10].

The neuroscience of fetal development is influenced by what the mother is getting in her diet. The placenta isn’t just a passive gateway for nutrients. It has a fully developed control system, for the management of the growth and development of the fetus, and the control of substrate hormones and signaling to the fetus. The brain and other fetal organs rely on the placenta for the provision of nutrients. Deficiencies of micronutrients and other nutrients can adversely affect placental function, in turn [11], decreasing the improvement of maternal nutrition and the position of the fetus within the womb.

The placental production of growth factors, cytokines, and neuroactive molecules interacts with fetal neural progenitors and glial cells, contributing to brain maturation and circuit formation. The development of the fetal brain is influenced by factors unrelated to direct nutrition that are also produced by the placenta [12]. The absence of free fetal micronutrients does not bare the deficiency of fetal brain development. Understanding the neurodevelopmental outcomes of the fetus and the mother's nutrition is a complex process and the management of the nutrients the mother consumes offers a way to guide the process.

Research shows that the impact of maternal micronutrient deficit on the neurodevelopment of the fetus may be detectable even before behavioral or cognitive symptoms are present postnatally. Biomarkers of neurodevelopment that may be present in the placenta and umbilical cord signify some kind of neurodevelopmental signaling of the fetus. This is indicative of some form of in utero programming [13]. The presence of neurotrophins, growth factors, proteins related to the myelination process, and other neuroregulatory metabolic substances can all be indicators of neuronal maturation. These indicators can also provide insight on the fetal neurodevelopmental condition, and the timing can be optimal for action to be taken.

Assessing the biomarkers of fetal neurodevelopment in the cord blood also has additional benefits. It is a combination of all the maternal and fetal biochemical constituents when the fetus is moving from an intrauterine to an extrauterine environment. It embodies all of the previous maternal and fetal metabolic interactions, the function of the placenta, and all the maternal biochemical constituents [14]. The neurodevelopmental biomarkers contained in cord blood demonstrate the possibility of a previously unattainable developmental stage of the fetus. The ability to collect cord blood is also an added benefit. It is an uncomplicated and non-invasive method that is found in all of the clinical setups. It vastly increases the ability to apply this method in practice.

Along with the assessment of cord blood, the placental tissue analysis will add more analytical dimensions regarding the location and the mechanisms of the channels that transport and signal the nutrients that affect the developing fetal brain. The placental expression of the field's nutrient transporters, epigenetic modulators, and neurodevelopmental genes, the programming of the placental constituents due to maternal micro nutrient insufficiency can be described [15]. Considering all of these aspects, the cord blood and placental tissue constituents, maternal malnutrition, and the placental neurodevelopment constituents, from a dual perspective, can be placed within the framework of systemic vs local tissue dimensions.

The rationale for a biomarker-based investigation is further strengthened by the variety of neurodevelopmental outcomes that differ from one fetus to another, even in the case of maternal micronutrient deficiency. The absence of a specific growth deficit of the fetus may suggest the presence of compensatory and the mechanisms of varying responsive pathways. Biomarkers serve to document heterogeneity by assessing the difference at a molecular level that may underlie the expression of specific traits [16].

This is consistent with the more contemporary approaches to the complex models of the Developmental Origins of Health and Disease, which focus on latent risk and the early programming of the life pathways that lead to disease. Although the significance of maternal micronutrients in the neurodevelopment of the fetus is being increasingly recognized, there is a large gap in the understanding of measurable fetal biomarkers that are related to specific deficiencies. A majority of prior research has depended on neurodevelopmental assessments after birth and maternal dietary recalls, which is temporally imprecise and lacks specific mechanisms. The integration of biochemical biomarkers in the cord blood and placental tissue provides a more definitive relationship of the status of fetal neurodevelopment to the maternal micronutrients to the maternal micronutrients [17]. This approach is more than associative epidemiology and is a step closer to a systems-level understanding of neurodevelopmental programming related to the nutrients available to the fetus.

From this perspective, the current research attempts to establish the link between maternal micronutrient deficiency and neurodevelopmental biomarkers of the fetus at birth. By conceptualizing micronutrient deficiency as biochemical stress mediated through the placenta–fetal axis and evaluated using molecular biomarkers, this research endeavors to explain how maternal nutrient buffers influence the neurodevelopmental pathways infants are predisposed to. This focused understanding is critical to the development of screening programs during pregnancy, delineating sub-populations that are at greater risk, and designing specific nutritional programs during pregnancy.

2. Methodology

This research study intends to examine the biological link between maternal micronutrient status and signaling related to the neurodevelopment of the fetus, utilizing an integrated framework based on biomarkers. Rather than solely considering micronutrient intake, the design shifts to the biochemical aspects and focuses on the placental transfer of a micronutrient and the expression of a biomarker in the fetus as critical and sequential components of neurodevelopment. A systems-level analysis of the maternal nutrient status, the placental intercession, and the fetal biomarker reaction is formulated in the form of a pipeline. Within this framework, the maternal nutrient status is captured, and the subsequent placental and fetal responses are modeled schematically in Figure 1.

To construct the study cohort, a range of maternal micronutrient deficiency and sufficiency during pregnancy was represented, and the study aimed to reduce other confounding factors not related to nutritional biology. Pregnant women were recruited in the late second and/or early third trimester, which is the stage of development when fetal brain growth and synaptogenesis are complemented by myelination. This period also guaranteed that maternal micronutrient status was reflective of the cumulative exposure during the pregnancy, as it was the most relevant to the neurodevelopment of the fetus. A review of the maternal medical records was conducted to detail the gestational age, parity, body mass index, the use of prenatal supplements, and any other associated clinical conditions that may interfere with the metabolism of micronutrients and the function of the placenta.
The first analytical layer of the workflow shown in Figure 1 includes the evaluation of maternal micronutrients.

In the study, blood samples collected during late gestation were evaluated for the presence of the neurodevelopmentally relevant micronutrients, iron, iodine, folate, vitamin B12, and zinc. Out of the numerous neurodevelopmentally relevant micronutrients, these five are the most relevant because they are major constituents for the formation of new neurons, synthesis of neurotransmitters, epigenetic modification, and myelination. The various micronutrients were quantified using standard biochemical assays that are specific to each micronutrient and are sensitive to both the physiological and deficient ranges. Rather than classifying maternal micronutrient status as a deficiency, the status was treated as a continuous biological variable. This approach enabled the modeling of downstream effects in a manner that considered dose-dependent factors.



Figure 1. Software-style analytical workflow for micronutrient–neurodevelopment linkage

The second layer of the framework examined the modulation and transfer of micronutrients via the placenta. During delivery, placental tissue was sampled according to the standardized sampling protocol, which attempts to capture all the placental tissue heterogeneities. To address the differential placental surface areas and their interactions with maternal and fetal blood, tissue was sampled from the maternal and fetal sides of the placenta. The placental biomarkers included various micronutrient transporters, placental binding proteins and enzymes of placental nutrient metabolism, and neurodevelopment molecules. The placental profiling step recognizes the placental barrier as an active, and not passive, buffer and amplifier, or modifier, for maternal micronutrient signals prior to fetal exposure.

The analysis of placental neurodevelopment signals overlapped with the placental markers of micronutrients. These included neurodevelopmental growth factors and neurotrophic signals and proteins and markers of neurogenesis and axonogenesis. The framework, by seeking the nexus of neurodevelopment signals and vitamin

transport, addresses the hypothesis that a declining maternal micronutrient status has a direct or unmediated effect on fetal exposure. This two-pronged analysis of the placenta serves as a vital link between maternal biochemistry and fetal development.

The fetal biomarker layer is the third integral element of the pipeline. Within the first minutes of life, cord blood was collected. It contained the fetus' internal biochemical environment at the completion of gestation. Cord blood was chosen as the first bio-matrix due to its composition, reflecting maternal nourishment, placental health, and fetal metabolic activity. Neurodevelopmental biomarkers present in cord blood, which include neurotrophic factors, developmental growth factors, and metabolic markers of neuronal and synaptic maturation, were chosen to reflect functional developmental attributes of the brain, as opposed to structural ones, which are not present at birth.

Also of significance, the capturing of patterns to fetal biomarker analysis was executed to show coordinated biological processes as opposed to individual patterns of change to markers. Each individual biomarker was normalized in value, and in the context of multivariate analyses, patterns were identified in response to different levels of maternal micronutrient deficiency. This approach, itself, illustrates the complexity of interrelated molecular networks that govern fetal neurodevelopment. It is due to the fact that the inhibition of one micronutrient network is likely to affect multiple downstream networks. Hence, the analytical approach was focused on the patterning and holistic modeling, as opposed to single markers.

We understand that data normalization and pre-processing is important for both analytical integrity and reproducibility. For example, the concentrations of maternal, placental, and fetal biomarkers were adjusted with a log transformation (if applicable) and then standardized for bias and scaled for cross-analyte comparison. Statistical methods were used to Assessed and Correct methods to address batch effects from the timing of the assay and reagents. These pre-processing steps are incorporated into the workflow represented in Figure 1 for the purposes of maintaining transparency and procedural integrity.

The modeling framework layer consolidated the data from all three biological compartments. The biomarker space was statistically analyzed using multivariate analysis to identify relationships between maternal micronutrients, placental biomarkers, and fetal neurodevelopment. From the biomarker space, regression modeling determined the degree of impact of selected micronutrients on fetal biomarkers Dimensions and regression modeling created in the biomarker space. The modeling of all three compartments allows for the analysis of both direct and indirect pathways in maternal micronutrients and fetal neurodevelopment signaling.
Study design features include the alignment of cohort traits and biomarker analysis, captured in Table 1. To contextualize biomarker findings, maternal and fetal demographic variables such as gestational age at delivery, fetal sex, and birth weight percentile, were captured. Though these were not primary explanatory variables, they were included as covariates when applicable, for the purposes of effect isolation, particularly for micronutrients.

Table 1 also details the scope of the profiling framework by summarizing the micronutrients analyzed and the respective biological matrices.

Table 1. Maternal and fetal cohort characteristics + micronutrients assessed

Parameter	Value / Description
Mother–infant dyads (n)	68
Maternal age (years, mean ± SD)	27.9 ± 4.6
Gestational age at delivery (weeks, mean ± SD)	38.1 ± 1.9
Birth weight percentile (mean ± SD)	42.7 ± 18.3
Fetal sex (male / female, %)	52.9 / 47.1
Biological matrices analyzed	Maternal blood · Placental tissue · Cord blood
Micronutrients assessed	Iron, Iodine, Folate, Vitamin B12, Zinc

For comparative analyses, the cohort was post hoc stratified by maternal micronutrient status. Stratification thresholds were based on clinically established reference ranges complemented by population distributions, which created groups of insufficient, moderate, and adequate micronutrient status. This approach facilitated the examination of graded biological responses, as opposed to merely binary deficiency impacts. Notably, the analysis of fetal and placental biomarkers occurred independently of clinical neurodevelopmental outcomes, which may be unassessable at birth, highlighting the study's focus on biomarkers.

Incorporating ethical measures into the design of the study was crucial. Putting a further drain on participant resources was avoided by collecting all biological specimens as part of routine obstetric care or right after delivery. During informed consent, the focus was on the collection of samples pertaining to biomarker studies of fetal development. Participant confidentiality was ensured through anonymized data, secure data handling, and confidentiality procedures throughout the data analysis process.

The analytical pipeline in Figure 1 is designed to modular and reproducible. Independent validation and future extension can be accomplished for any step along the pipeline, from maternal assessment to fetal biomarker modeling. This feature promotes the possibility to scale the pipeline to larger cohorts as well as to adjust the pipeline to new micronutrients and neurodevelopmental markers, as the field progresses. The study design fosters replication and comparison across cohorts, which is crucial for progress in biomarker-driven prenatal research. This is accomplished through the documentation of every step in the workflow.

The outline of the study design along with the biomarker profiling framework represents an advancement from an evaluative nutritional assessment to the more descriptive assessment of the programming of neurodevelopment in the fetus. This framework is the first of its kind that combines and analyses maternal micronutrient status with placental mediation and fetal biomarker expression, thereby providing an integrated and holistic approach to the problem of prenatal biomarker nutritional environments and early neurodevelopment. The structure provided here lays the groundwork for the following sections in which we will discuss in detail, specific patterns of biomarkers and their associated functions.

3. Results: Fetal Neurodevelopmental Biomarker Alterations

This section outlines the primary findings regarding the relationship between lack of maternal micronutrients and the coordinated changes in fetal neurodevelopmental biomarkers at birth. The analysis here does not center on individual molecular changes, but rather on structured biomarker profiles that capture composite expressions of neurodevelopmental signaling.

Figure 2 illustrates a heatmap of the fetal neurodevelopmental biomarkers from the cord blood, categorized according to maternal micronutrient status and z-score normalized for each biomarker and individual to highlight the relative differences. Applying hierarchical clustering to both the samples and the biomarkers showed a distinct fetal profile for each level of maternal micronutrient status. Neonates of mothers with sufficient micronutrients were grouped together and had a characteristic profile of neurotrophic and growth-associated markers that were relatively unaltered. Conversely, neonates of mothers with a micronutrient deficiency were separated into distinct profiles characterized by the coordinated downregulation of several core markers of neurodevelopment.



Figure 2. Heatmap of neurodevelopmental biomarkers stratified by maternal micronutrient status

The clustering pattern in figure 2 demonstrates the interconnected nature of fetal neurodevelopmental response to availability of specific micronutrients. brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and insulin-like growth factor 1 (IGF-1) are examples of such co-clustered biomarker modules and all three exhibited attenuated deficiency across the board. These three markers are pivotal in the survival of the neurons, synaptic plasticity and the growth of the axons. Their coordinated reduction, signifying a broad suppression of neurodevelopmental support, is rather concerning, as there are multiple pathways to neurodevelopmental support. Within the same cluster of markers of myelination and oligodendrocyte maturation, the same concern is raised to the multiple deficiency impacts of micronutrients to neural development that are concurrently working to the same outcome.

The heatmap also responds in a graded rather than in a binary response. In the presence of moderate deficiency of maternal micronutrient, fetuses often placed themselves in the positions wherein the fetal development is neurobiologically held between the adequate maternal micronutrient and the severely deficient clusters. In doing so, partial neurodevelopmental signaling is preserved. Strength supports the notion that the vulnerability of fetal development is directly related to the micronutrient deficiency in the mother. If the scaled graded clustering did not exist, there would not be dune studies to derive an explanation. Especially in figure 2, where random variation or a lack of specific stress could guide from nothing, there is an undeniably biological explanation to be drawn. Even though hierarchical clustering gives a clear overview of how biomarkers are organized, we need a different, more quantifiable method of analysis: multivariate projection. In Figure 3, we see the multivariate stratification of fetal biomarker profiles. The method of analysis here is dimensionality reduction through techniques such as principal component analysis or UMAP. The analysis shows that the fetal samples are positioned according to the nutrient status of the mother. Within the samples are sufficient and insufficient groups, and the overlap is minor. The explanations of variance show that the large majority of variance across the biomarkers is captured by the first two components as evidenced by the analysis that there is a large total biomarker variability.



Figure 3. Multivariate stratification (PCA / UMAP) of fetal biomarker profiles

In Figure 3, the samples are positioned in a way that shows the analysis of the data is based on several different biomarkers rather than one extreme value. In the regions where the expression of neurotrophic and the growth factor are higher, we find those with adequate exposure. In the places where we have less expression of neurodevelopmental signaling, we find those with deficient exposure. The intermediate groups are positioned

along the access between the two extreme locations. They correspond to the graded pattern we see in Figure 2. The consistency of clustering and multivariate projection increases our confidence that there is a coherent biological state associated with the biomarker changes concerning the micronutrients present in the maternal system.

The multivariate framework also sheds light upon the relative contributions of the various biomarkers. Loadings relating to the main axes of variation demonstrate that neurotrophic factors and growth regulators are disproportionately influential to group separation, whereas markers of metabolism or stress have a more minimal influence. This finding indicates maternal micronutrient deficiency most severely impacts pathways related to neuronal growth and maturation, rather than creating an overall fetal stress phenomenon. That level of specificity aligns with the appropriate and documented roles micronutrients have in the neurodevelopmental process.

While analysing the patterns and relating them to specific biomarkers, Table 2 captures the neurodevelopmental biomarkers most impacted by maternal micronutrient deficiency. In order to help the reader understand the scope of each biomarker, I have presented the direction of change, effect size, and the adjusted p-value for each biomarker so that I can guide a more informed understanding of the impact of the deficiency. BDNF is clearly one of the most impacted markers, and in fact there is a well-documented drop of BDNF levels in fetuses whose mothers have suffered from deficiency during pregnancy. BDNF is associated with synaptic formation and plasticity and so the drop in BDNF levels establishes a pathway by which prenatal micronutrient deficiency alters neural circuitry formation.

Table 2. Key neurodevelopmental biomarkers associated with micronutrient deficiency

Biomarker	Neurodevelopmental role	Direction of change (deficient vs adequate)	Effect size (Cohen's d)	Adjusted significance (FDR-p)
BDNF	Synaptic plasticity, neuronal survival	↓ Decreased	−0.92	< 0.001
NGF	Neuronal differentiation, axonal growth	↓ Decreased	−0.74	0.003
IGF-1	Brain growth, myelination support	↓ Decreased	−0.88	< 0.001
MBP	Myelin sheath formation	↓ Decreased	−0.61	0.008
PLP1	Oligodendrocyte maturation	↓ Decreased	−0.55	0.015
OLIG2	Oligodendrocyte lineage commitment	↓ Decreased	−0.49	0.021

Similar to BDNF, NGF shows a negative correlation with a maternal micronutrient deficiency, though it is in the case with a slightly smaller effect size. NGF is essential for the survival and differentiation of certain neuronal subtypes. Its reduction may indicate early lineage specification in neurons. IGF-1 is shown to be positively correlated. Deficiencies are in line with IGF-1 function since it is related to brain development, production of neurons, and myelination. His reduced levels in the deficient group corresponds to the numerous studies, both experimentally and clinically, that connect nutrition deficiency to a stunted brain development.

Deficiencies in maternal micronutrients also correlate with myelination and oligodendrocyte maturation, detailed in another of the studies included in Table 2. Myelin, a key component in neural cells, is synthesized with the aid of nutrients, especially iron, iodine, and vitamin B12. The deficiency of these nutrients also affect the neural development modulated by thyroid hormones. The coordinated reduction of these markers supports the explanation of maternal micronutrient deficiency having an effect not just on neuronal growth and the deficiency of micronutrients alters the timing and the process of myelination.

The corrected value of significant associations in Table 2 suggests that the associations are strong and less likely to be the result of statistical error. In addition, the relative magnitudes of the effect sizes correspond to the visual spacing in Figures 2 and 3. This shows that we are providing cross-validation through different analytical methods. The strongest effect size biomarkers are the most significant and driving the clustering and multivariate separation, thus strengthening the results we present.

Figure 2 and 3, along with Table 2, show a clear story of the relationship between maternal micronutrient deficiency and the coordinated suppression of fetal neurodevelopmental biomarkers at birth. This suppression includes the neurotrophic support, growth regulation, and myelination processes, suggesting that it is a wide-ranging effect on developmental programming, as opposed to the disruption of a singular pathway. The proportionality of the alterations in the biomarkers suggests that the signaling for fetal neurodevelopment from maternal micronutrient deficiency is graded.

From the perspective of developmental biology, findings support the idea that there are specific time frames during which the presence of adequate micronutrients affects the neural development in a more positive way. The biomarkers assessed here have a neural activity that occurs in late gestation, which is a period of rapid increase in synapse formation and the initiation of myelin sheath formation. Changes are observed at birth and could be the result of a disrupted signal during critical pathways of development, rather than temporary changes around the time of delivery.

From a clinical perspective, the presence of the pattern of biomarkers of deficiency in maternal micronutrients and lack of development of the fetus is a positive sign. The biomarker changes provide evidence that even when the fetus appears to have a lack of development, there is a weak latent presence of a problem that could result in difficulties later during the course of life. The biomarker approach allows the clinical staff to assess which infants are at risk so as to promote timely clinical interventions before developing behavioral or cognitive problems.

4. Functional and Predictive Implications

This section combines the previously described changes in the biomarkers with fetal specific neurodevelopment trajectory and risk predictive functions in describing the biomarkers alterations. The analyses go beyond describing the associations by linking the maternal micronutrient burden to fetal neurodevelopment and

subsequent risk stratification, thereby contributing to the neurodevelopmental deficit predictive biology. The analyses keep referring to Table 3, Figures 4 and 5 to ensure predictive utility and functional understanding of the implications in neurodevelopmental risk stratification to change in biomarkers described to ensure that the analyses are empirically grounded and not conjectured.

Using a three dimensional correlation surface, Figure 4 demonstrates how the cumulative maternal micronutrient deficiency relates to the fetal neurodevelopmental biomarker indices. One axis of the surface represents the cumulative micronutrient deficiency, and the other represents the composite score of the fetal neurodevelopmental biomarker. The response dimension illustrates the overall integrity of the signaling neurodevelopment. Due to the non-linear topology, it shows that the presence of micronutrient deficiency is not a proportional factor in fetal neurodevelopment. The fetal biomarker indices are in a relatively stable position despite the deficiency in maternal nutrition, indicating that the placenta or the fetus may be compensatory at low levels. However, the surface descends steeply beyond a critical point of maternal micronutrient burden, indicating that the neurodevelopmental deficiency signal has deteriorated.



Figure 4. Correlation surface linking maternal micronutrient burden to fetal neurodevelopmental indices

The threshold-like behaviour noted in Figure 4 seems to be of special significance. It shows that the placental and fetal systems can adapt to a given amount of micronutrient deficiency, but within a certain set of parameters. It appears that once this set of adaptive capacities is exceeded, the neurodevelopmental systems of the fetus cannot maintain signaling homeostasis. The steep regions of the surface correspond to the levels of deficiency of neurotrophic factors and myelination markers, highlighted in the earlier sections. The responsive surface behaviour and the biomarker patterning convergence reflects the stressor nature of maternal micronutrient deficiency.

From a developmental viewpoint, the correlation surface in Figure 4 lends support to the idea of sensitive periods in the case of fetal brain development. The indices of neurodevelopment show a decreasing trend that is non-linear, suggesting that there might be an interaction of the 'deficiency' construct with the timing and the severity of the deficiency and the outcome magnitude. Hence, the impact could be severe for the neurodevelopment of the fetus who has suffered deficient conditions for a long period of time late in gestation, a period of rapid synaptogenesis and primitive myelination. This explanation stems solely from the response surface structure and is not a post hoc inference, thus providing a reasonable and quantitative justification for the long-held hypotheses of developmental nutrition.

In Figure 4, we explore the functional relationships; in Figure 5, we explore the predictive abilities of fetal neurodevelopmental biomarkers. Figure 5 shows an example of a predictive classification model where multilayer biomarker inputs are translated into neurodevelopmental risk probabilities using a machine learning-based decision surface. This model is different from a set of simple linear classifiers or single threshold markers in that it combines multiple biomarker inputs and estimates the risk on a continuum for neural development. The decision boundary created yielded low, intermediate, and high neurodevelopmental risk and was aligned with different levels of maternal micronutrient gaps.



Figure 5. Predictive classification model for neurodevelopmental risk

The construction of the predictive surface suggests that the risk for neurodevelopment is not caused by extreme changes of one single biomarker but rather by changes across multiple neurotrophic, growth, and myelination-related biomarkers. Samples characterized in the model as high risk are in areas of the feature space where BDNF, IGF-1, and myelination markers are all suppressed, which fits the biomarker pattern findings in Figures

2 and 3. On the other hand, low-risk classifications are in areas that neurodevelopmental signaling is preserved across these domains. Intermediate-risk areas demonstrate patterns that are consistent with partial preservation, matching the grading of responses of the clustering and PCA analyses.

Most importantly, the predictive model shows that even the lack of clinical signs at birth, biomarker-derived risk estimation models can pinpoint neurodevelopmental risk. This can be very important because a lot of neurodevelopmental problems occur months or years post-delivery. The model in Figure 5 utilized cord-blood and placental biomarkers to lay the groundwork for the identification of infants who may need additional developmental surveillance and/or specialized nutritional interventions. The nature of the model output supports clinical practice by explaining a range of risks rather than a simple yes or no answer.

Table 3 summarizes the neurodevelopmental predictive and functional findings contextualized by maternal micronutrient deficiency levels. The systematic differences in deficiency levels help to delineate the differences in indices of fetal biomarker-derived risk. The low deficiency group has biomarker profiles aligned with no disruption of neurodevelopmental signaling and a low risk from the neurodevelopmental predicted risk. The moderate deficiency group has a slight disruption in biomarker profiles including a decreased neurotrophic factor coupled with an increased predicted risk. The biomarker profiles of the severe deficiency group correlate with the increased neurodevelopmental predicted risk.

Table 3. Neurodevelopmental risk indicators stratified by micronutrient status

Indicator	Low deficiency	Moderate deficiency	Severe deficiency	Adjusted significance
Neonates (n)	26	22	20	—
Composite neurodevelopmental biomarker index (mean ± SD)	0.82 ± 0.21	0.57 ± 0.19	0.31 ± 0.17	< 0.001
Reduced neurotrophic support (BDNF/NGF below median), %	15.4	36.4	70.0	< 0.001
Impaired growth signaling (IGF-1 below median), %	19.2	40.9	65.0	0.002
Myelination-related marker suppression, %	11.5	31.8	60.0	< 0.001
Predicted high neurodevelopmental risk, %	7.7	27.3	55.0	< 0.001

The stratified results from Table 3 correlate with the correlation surface in Figure 4 and the classification surface in Figure 5, showing consistency across various forms of data analysis. The differences are likely not random given the statistical significance embedded within the findings of the Table. The combination of stratified groups, machine learning classification, and continuous response modeling provide us with strengthened biological reasoning for the findings.

Integrating Figures 4 and 5 and Table 3 shows the possible value of risk models associated with biomarkers in prenatal and perinatal care. Instead of relying on maternal dietary histories or assessments of postnatal development, this model uses biochemical markers to provide an objective indication of neurodevelopmental

risk at the time of birth. This type of risk stratification could lead to individualized follow-up plans, which may include nutritional supplementation, neurodevelopmental screening, or parent guidance counseling.

These findings also add to the new frameworks for understanding fetal programming. The varying degrees of non-linearity and the multivariate relationships and predictive analytics point towards the maternal micronutrient milieu and the complexity of system-wide neurodevelopmental mechanisms. This allows us to move past the neural model of simple deficiencies to an understanding of the comprehensive and integrated model of nutritional sufficiency. In this case, the biomarkers create a quantifiable link between maternal nutrition, placental function, and neurodevelopmental outcomes in the fetus.

5. Conclusion

This investigation reveals the existence of the micronutrient-sensitive temporal windows with regards to the biochemical maternal-fetal interface that uniquely modulates neurodevelopment signaling during the fetal neurodevelopment process. The shifts that ensue with maternal micronutrient concentration across neurotrophic, growth, and myelination biomarkers signal the fetal brain to the biochemical systems pathway, as opposed to the isolated pathway response. Consistently, these results confirm that the quality of prenatal nourishment dictates the neurodevelopment of a fetus by activating amalgamated systems during a neurodevelopmental critical window for brain formation.

The use of the biomarker concept in this study demonstrates the untapped capacity of biomarkers as neurodevelopmental risk indicators. The risk published from birth biomarkers are the result of the cumulative impact of uterine exposures and the placenta, which capture the latent risk that remains unrecognized from the standard clinical or anthropometric methods. This research also validates the use of biochemical profiling in the risk assessment process, complemented with a pathway-based rationale for early neurodevelopment programming by maternal micronutrient deficiency.

The findings have important implications for prenatal screening and the interventions that can be taken after screening. Noting the risk-adjusted micronutrient biomarker will allow the screening and intervention processes to move away from generalized nutrition suggestions to more individualized plans. These plans can be more appropriate and effective based on the individual antenatal micronutrient levels and the fetal response at the time of pregnancy screening. Identifying high-risk pregnancies and newborns/children will allow the provision of optimal nutrition for the required developmental level and surveillance support. This will help to reduce the risk of longer-term consequences in the neurodevelopment of the target individual.

In summary, measurable biomarker correlates at birth show and underscore the importance of maternal micronutrient deficiency and its impact on the signaling for fetal neurodevelopment. The combination of maternal, placental, and fetal biomarkers together provides a framework and growing understanding of how and

why the prenatal nutritional environment impacts early brain development. Further research in this area, along with increased understanding of the maternal, placental, and fetal biomarker combination, will help to increase predictive capability and refine the understanding of distinct intervention strategies as well as nutritional programming of the developing human brain.

References

1. Cusick, Sarah E., Amanda Barks, and Michael K. Georgieff. "Nutrition and brain development." *Sensitive periods of brain development and preventive interventions*. Cham: Springer International Publishing, 2021. 131-165.
2. Georgieff, Michael K. "Early life nutrition and brain development: breakthroughs, challenges and new horizons." *Proceedings of the Nutrition Society* 82.2 (2023): 104-112.
3. Bastian, Thomas W., et al. "The effects of early-life iron deficiency on brain energy metabolism." *Neuroscience insights* 15 (2020): 2633105520935104.
4. Preau, Laetitia, et al. "Thyroid hormone signaling during early neurogenesis and its significance as a vulnerable window for endocrine disruption." *Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms* 1849.2 (2015): 112-121.
5. Kucha, Winner, et al. "Folate, vitamin B12, and homocysteine levels in women with neural tube defect-affected pregnancy in Addis Ababa, Ethiopia." *Frontiers in nutrition* 9 (2022): 873900.
6. Malcomson, F. C., and J. C. Mathers. "Nutrition, epigenetics and health through life." *Nutrition Bulletin* 42.3 (2017): 254-265.
7. Kumar, Vijay, et al. "Zinc deficiency and its effect on the brain: an update." *Int J Mol Genet Gene Ther* 1.1 (2016): 1-7.
8. Gallo, Milagros, and Fernando Gámiz. "Choline: an essential nutrient for human health." *Nutrients* 15.13 (2023): 2900.
9. Bailey, Regan L., Keith P. West Jr, and Robert E. Black. "The epidemiology of global micronutrient deficiencies." *Annals of nutrition and metabolism* 66.Suppl. 2 (2015): 22-33.
10. Santander Ballestín, Sonia, et al. "Is supplementation with micronutrients still necessary during pregnancy? A review." *Nutrients* 13.9 (2021): 3134.
11. Lewis, Rohan M., Jane K. Cleal, and Keith M. Godfrey. "The placental role in developmental programming." *Reproductive and Developmental Toxicology*. Academic Press, 2017. 1245-1258.
12. San Juan-Reyes, Sindy, et al. "Oxidative stress in pregnancy complicated by preeclampsia." *Archives of biochemistry and biophysics* 681 (2020): 108255.
13. Nesse, Randolph M., and George C. Williams. "Evolution and the origins of disease." *Health Psychology*. Routledge, 2016. 167-173.
14. Lopez, Marcela, et al. "The social ecology of childhood and early life adversity." *Pediatric research* 89.2 (2021): 353-367.
15. Mo, Jiaying, et al. "Developmental origins of adult diseases." *Medical Review* 2.5 (2022): 450-470.
16. Lautarescu, Alexandra, Michael C. Craig, and Vivette Glover. "Prenatal stress: Effects on fetal and child brain development." *International review of neurobiology* 150 (2020): 17-40.
17. Manokhina, Irina, et al. "Placental biomarkers for assessing fetal health." *Human Molecular Genetics* 26.R2 (2017): R237-R245.